{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:14:33Z","timestamp":1787933673645,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006379","name":"VA office of Research and Development","doi-asserted-by":"crossref","award":["I01 RX001305-01A2"],"award-info":[{"award-number":["I01 RX001305-01A2"]}],"id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["X01 NS073526-01A1"],"award-info":[{"award-number":["X01 NS073526-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prominent activation of microglial immune\/inflammatory processes is a characteristic feature of brains of patients with tauopathies including Alzheimer\u2019s disease (AD), suggesting that neuroinflammation may be a critical factor in their pathogenesis. Strategies aimed at developing new therapeutics for tauopathies based on anti-inflammation or immunomodulation are likely to be promising avenues of research. We previously developed JM4\u2014a 19\u2019mer cyclic peptide derived from the first loop of human erythropoietin. This peptide possesses beneficial immune modulatory and tissue protective effects while lacking the undesirable side effects of full-length erythropoietin. In this preclinical study, we investigated the effect of chronic JM4 treatment on the PS19 mouse that carries the P301S mutant human tau gene, linked to a form of frontotemporal dementia. This transgenic mouse has been widely used as a model of tauopathies including AD and related dementias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Daily subcutaneous treatment of female PS19 mice with JM4 was initiated before disease onset and continued on for the animals\u2019 lifespan. The progression of neurological deficit and the lifespan of these mice were assessed. To evaluate the effect of JM4 treatment on cognition of these animals, the PS19 mice underwent Barnes maze test and elevated plus maze test. In addition, neuronal loss, phosphorylated tau aggregation, and microglial activation were assessed using immunohistochemistry of PS19 mouse brain sections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>JM4 treatment of PS19 mice initiated before disease onset reduced neurological deficit, prolonged lifespan, and rescued memory impairment. The beneficial effects of JM4 were accompanied by reductions in neuronal loss, phosphorylated tau aggregation, and microglial activation in the PS19 mouse brain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Limitations<\/jats:title>\n                <jats:p>Use of a\u00a0single dose of JM4 and female mice only.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>JM4 is a potential novel therapeutic agent for the treatment of tauopathies including AD and related dementias.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-020-00766-4","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:03:23Z","timestamp":1611745403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-823X","authenticated-orcid":false,"given":"Yun-Beom","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrose A.","family":"Dunn-Meynell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeya","family":"Gaindh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"766_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"766_CR2","first-page":"515248","volume":"2015","author":"ME McCaulley","year":"2015","unstructured":"McCaulley ME, Grush KA. Alzheimer\u2019s disease: exploring the role of inflammation and implications for treatment. Int J Alzheimers Dis. 2015;2015:515248.","journal-title":"Int J Alzheimers Dis"},{"key":"766_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777\u201383.","journal-title":"Science."},{"key":"766_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer\u2019s disease. Neurobiol Aging. 2000;21:383\u2013421.","journal-title":"Neurobiol Aging"},{"key":"766_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.4397","volume":"23","author":"MW Salter","year":"2017","unstructured":"Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23:1018\u201327.","journal-title":"Nat Med"},{"key":"766_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.phrs.2018.01.017","volume":"130","author":"C Balducci","year":"2018","unstructured":"Balducci C, Forloni G. Novel targets in Alzheimer\u2019s disease: a special focus on microglia. Pharmacol Res. 2018;130:402\u201313.","journal-title":"Pharmacol Res"},{"key":"766_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712\u20136.","journal-title":"Science."},{"key":"766_CR8","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"110","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic B, Huntley MA, De Mazi\u00e8re A, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron. 2018;110:1322\u201336.","journal-title":"Neuron."},{"key":"766_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.neuron.2018.10.031","volume":"100","author":"A Litvinchuk","year":"2018","unstructured":"Litvinchuk A, Wan YW, Swartzlander DB, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer\u2019s disease. Neuron. 2018;100:1337\u201353.","journal-title":"Neuron."},{"key":"766_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.celrep.2019.07.060","volume":"28","author":"T Wu","year":"2019","unstructured":"Wu T, Dejanovic B, Gandham VD, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 2019;28:2111\u201323.","journal-title":"Cell Rep"},{"key":"766_CR11","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s12272-015-0648-x","volume":"38","author":"S Shadfar","year":"2015","unstructured":"Shadfar S, Hwang CJ, Lim MS, Choi DY, Hong JT. Involvement of inflammation in Alzheimer\u2019s disease pathogenesis and therapeutic potential of anti-inflammatory agents. Arch Pharm Res. 2015;38:2106\u201319.","journal-title":"Arch Pharm Res"},{"key":"766_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","volume":"31","author":"A Ardura-Fabregat","year":"2017","unstructured":"Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, et al. Targeting neuroinflammation to treat Alzheimer\u2019s disease. CNS Drugs. 2017;31:1057\u201382.","journal-title":"CNS Drugs"},{"key":"766_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1021\/acschemneuro.8b00402","volume":"10","author":"W-Y Fu","year":"2019","unstructured":"Fu W-Y, Wang X, Ip NY. Targeting neuroinflammation as a therapeutic strategy for Alzheimer\u2019s disease: mechanisms, drug candidates, and new opportunities. ACS Chem Neurosci. 2019;10:872\u20139.","journal-title":"ACS Chem Neurosci"},{"key":"766_CR14","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Sprin Harb Perspect Med. 2011;1:a006189.","journal-title":"Cold Sprin Harb Perspect Med"},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:22\u201335.","journal-title":"Nat Rev Neurosci"},{"key":"766_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ajpath.2011.05.047","volume":"179","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Mielke ML, G\u00f3mez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer\u2019s disease. Am J Pathol. 2011;179:1373\u201384.","journal-title":"Am J Pathol"},{"key":"766_CR17","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1523\/JNEUROSCI.2868-05.2005","volume":"25","author":"M Kitazawa","year":"2005","unstructured":"Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer\u2019s disease. J Neurosci. 2005;25:8843\u201353.","journal-title":"J Neurosci"},{"key":"766_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337\u201351.","journal-title":"Neuron."},{"key":"766_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/brain\/awv081","volume":"138","author":"N Maphis","year":"2015","unstructured":"Maphis N, Xu G, Kokiko-Cochran ON, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138:1738\u201355.","journal-title":"Brain."},{"key":"766_CR20","doi-asserted-by":"publisher","first-page":"a011619","DOI":"10.1101\/cshperspect.a011619","volume":"3","author":"HF Bunn","year":"2013","unstructured":"Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med. 2013;3:a011619.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"766_CR21","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1096\/fj.05-3907fje","volume":"19","author":"I Yatsiv","year":"2005","unstructured":"Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 2005;19:1701\u20133.","journal-title":"FASEB J"},{"key":"766_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/ijms17030289","volume":"17","author":"KM Lan","year":"2016","unstructured":"Lan KM, Tien LT, Cai Z, et al. Erythropoietin ameliorates neonatal hypoxia-ischemia-induced neurobehavioral deficits, neuroinflammation, and hippocampal injury in the juvenile rat. Int J Mol Sci. 2016;17:289.","journal-title":"Int J Mol Sci"},{"key":"766_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.neulet.2007.08.022","volume":"425","author":"G Chen","year":"2007","unstructured":"Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett. 2007;425:177\u201382.","journal-title":"Neurosci Lett"},{"key":"766_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001924","volume":"3","author":"R Yuan","year":"2008","unstructured":"Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. Erythropoietin: a potent inducer of peripheral immuno\/inflammatory modulation in autoimmune EAE. PLoS One. 2008;3:e1924.","journal-title":"PLoS One"},{"key":"766_CR25","doi-asserted-by":"publisher","first-page":"114102","DOI":"10.1038\/sj.bjp.0707287","volume":"151","author":"L Torup","year":"2007","unstructured":"Torup L. Neuroprotection with or without erythropoiesis; sometimes less is more. Br J Pharmacol. 2007;151:114102.","journal-title":"Br J Pharmacol"},{"key":"766_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/26773","volume":"395","author":"RS Syed","year":"1998","unstructured":"Syed RS, Reid SW, Li C, Cheetham JC, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395:511\u20136.","journal-title":"Nature."},{"key":"766_CR27","doi-asserted-by":"publisher","first-page":"10925","DOI":"10.1073\/pnas.0805594105","volume":"105","author":"M Brines","year":"2008","unstructured":"Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008;105:10925\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"766_CR28","doi-asserted-by":"crossref","unstructured":"Shing KSCT, Broughton SE, Nero TL, et al. EPO does not promote interaction between the erythropoietin and beta-common receptors. Sci Rep. 2018;8:12457.","DOI":"10.1038\/s41598-018-29865-x"},{"key":"766_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","volume":"6","author":"AL Sir\u00e9n","year":"2009","unstructured":"Sir\u00e9n AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 2009;6:108\u201327.","journal-title":"Neurotherapeutics."},{"key":"766_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.1098313","volume":"305","author":"M Leist","year":"2004","unstructured":"Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239\u201342.","journal-title":"Science."},{"key":"766_CR31","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/brain\/awq101","volume":"133","author":"S Pankratova","year":"2010","unstructured":"Pankratova S, Kiryushko D, Sonn K, et al. Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain. 2010;133:2281\u201394.","journal-title":"Brain."},{"key":"766_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neurobiolaging.2019.05.003","volume":"81","author":"O Dmytriyeva","year":"2019","unstructured":"Dmytriyeva O, Belmeguenai A, Bezin L, et al. Short erythropoietin-derived peptide enhances memory, improves long-term potentiation, and counteracts amyloid beta\u2013induced pathology. Neurobiol Aging. 2019;81:88\u2013101.","journal-title":"Neurobiol Aging"},{"key":"766_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s13311-015-0379-1","volume":"12","author":"R Yuan","year":"2015","unstructured":"Yuan R, Wang B, Lu W, Maeda Y, Dowling P. A distinct region in erythropoietin that induces immuno\/inflammatory modulation and tissue protection. Neurotherapeutics. 2015;12:850\u201361.","journal-title":"Neurotherapeutics."},{"key":"766_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s13311-015-0418-y","volume":"3","author":"B Wang","year":"2016","unstructured":"Wang B, Kang M, Marchese M, et al. Beneficial effect of erythropoietin short peptide on acute traumatic brain injury. Neurotherapeutics. 2016;3:418\u201327.","journal-title":"Neurotherapeutics."},{"key":"766_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021050","volume":"6","author":"H Takeuchi","year":"2011","unstructured":"Takeuchi H, Iba M, Inoue H, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One. 2011;6:e21050.","journal-title":"PLoS One"},{"key":"766_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fnagi.2019.00252","volume":"11","author":"AA Dunn-Meynell","year":"2019","unstructured":"Dunn-Meynell AA, Dowling P, Marchese M, et al. In vivo bioluminescence imaging used to monitor disease activity and therapeutic response in a mouse model of tauopathy. Front Aging Neurosci. 2019;11:252.","journal-title":"Front Aging Neurosci"},{"key":"766_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","volume":"153","author":"BR Miller","year":"2008","unstructured":"Miller BR, Dorner JL, Shou M, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington\u2019s disease phenotype in the R6\/2 mouse. Neuroscience. 2008;153:329\u201337.","journal-title":"Neuroscience."},{"key":"766_CR38","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","volume":"33","author":"M Iba","year":"2013","unstructured":"Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer\u2019s-like tauopathy. J Neurosci. 2013;33:1024\u201337.","journal-title":"J Neurosci"},{"key":"766_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0165-0270(98)00169-1","volume":"87","author":"PN Pompl","year":"1999","unstructured":"Pompl PN, Mullan MJ, Bjugstad K, Arendash GW. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer\u2019s disease. J Neurosci Methods. 1999;87:87\u201395.24.","journal-title":"J Neurosci Methods"},{"key":"766_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0304-3940(95)11484-E","volume":"189","author":"M Goedert","year":"1995","unstructured":"Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognizes tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167\u20139.","journal-title":"Neurosci Lett"},{"key":"766_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bbrc.2007.04.187","volume":"358","author":"R Porzig","year":"2007","unstructured":"Porzig R, Singer D, Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun. 2007;358:644\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"766_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13195-015-0139-9","volume":"7","author":"DG Walker","year":"2015","unstructured":"Walker DG, Lue LF. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther. 2015;7:56.","journal-title":"Alzheimers Res Ther"},{"key":"766_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","volume":"19","author":"GW Kreutzberg","year":"1996","unstructured":"Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312\u20138.","journal-title":"Trends Neurosci"},{"key":"766_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-neuro-061010-113810","volume":"35","author":"AH Stephan","year":"2012","unstructured":"Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369\u201389.","journal-title":"Annu Rev Neurosci"},{"key":"766_CR45","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-018-0543-y","volume":"562","author":"TJ Bussian","year":"2018","unstructured":"Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, Baker DJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562:578\u201382.","journal-title":"Nature."},{"key":"766_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.1227901","volume":"339","author":"A Aguzzi","year":"2013","unstructured":"Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339:156\u201361.","journal-title":"Science."},{"key":"766_CR47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","volume":"173","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018;173:1073\u201381.","journal-title":"Cell."},{"key":"766_CR48","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","volume":"21","author":"S Hickman","year":"2018","unstructured":"Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21:1359\u201369.","journal-title":"Nat Neurosci"},{"key":"766_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.stem.2018.06.015","volume":"23","author":"A Sommer","year":"2018","unstructured":"Sommer A, Maxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson\u2019s disease. Cell Stem Cell. 2018;23:123\u201331.","journal-title":"Cell Stem Cell"},{"key":"766_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91\u2013101.","journal-title":"Clin Neuropharmacol"},{"key":"766_CR51","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1523\/JNEUROSCI.23-05-01605.2003","volume":"23","author":"Y Li","year":"2003","unstructured":"Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci. 2003;23:1605\u201311.","journal-title":"J Neurosci"},{"issue":"1","key":"766_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neuron.2010.08.023","volume":"68","author":"K Bhaskar","year":"2010","unstructured":"Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68(1):19\u201331.","journal-title":"Neuron."},{"key":"766_CR53","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jalz.2016.03.018","volume":"12","author":"DM Holtzman","year":"2016","unstructured":"Holtzman DM, Carrillo MC, Hendrix JA, et al. Tau: from research to clinical development. Alzheimers Dement. 2016;12:1033\u20139.","journal-title":"Alzheimers Dement"},{"key":"766_CR54","first-page":"CD006378","volume":"2","author":"D Jaturapatporn","year":"2012","unstructured":"Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2012;2:CD006378.","journal-title":"Cochrane Database Syst Rev"},{"key":"766_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12974-020-01749-w","volume":"17","author":"Y Sun","year":"2020","unstructured":"Sun Y, Guo Y, Feng X, et al. The behavioural and neuropathologic sexual dimorphism and absence of MIP-3\u03b1 in tau P301S mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2020;17:72.","journal-title":"J Neuroinflammation"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:09:21Z","timestamp":1611745761000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00766-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the mouse studies were conducted in accordance with the Animal Component of Research Protocol approved by IACUC at the VA New Jersey Health Care System, East Orange, NJ.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PCD: US Patent Title: Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders. Application serial number: 12\/792.336. Priority date: 1\/23\/2013, Filling date: 3\/11\/2013, Assignors: Peter Dowling. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}